Cynomolgus TNFRSF10D Protein

Sino Biological Inc. liefert Cynomolgus TNFRSF10D Protein mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über Cynomolgus TNFRSF10D Protein lesen Sie bitte: http://www.sinobiological.com/TNFRSF10D-Protein-g-10578.html

Produkt-Information von TNFRSF10D Protein

QC Testing von TNFRSF10D Protein

Purity	> 90 % as determined by SDS-PAGE	SDS-PAGE: TNFRSF10D protein
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	Ala 56
Molecular Mass	The recombinant cynomolgus TNFRSF10D is a disulfide-linked homodimer. The reduced monomer comprises 392 amino acids and has a calculated molecular mass of 42.9 KDa.The apparent molecular mass of the protein is approximately 52-56 KDa respectively in SDS-PAGE.
Formulation	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide von TNFRSF10D Protein

Verwandte Produkte & Themen von TNFRSF10D Protein

TNFRSF10D Protein Description

TNF-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand and TNFSF10, are TNF superfamily members, and preferentially induces apoptosis in tumor cell lines, but not in normal cells. TRAIL binds at least five different receptors with characteristic cysteine-rich repeats. Human TRAILR4, also known as decoy receptor 2 (DcR2) and TRUNND (TRAIL receptor with a truncated death domain), is a member of the TNF receptor superfamily and is referred to as TNFRSF10D. TRAILR4 shows a unique expression pattern in human tissues and is particularly abundant in fetal liver and adult testis. This protein is a type 1 transmembrane receptor consisting of an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplamic death domain. Accordingly, TRAILR4 is not capable of activating TRAIL-mediated NF-kappaB or apoptosis pathways, and identified as an antiapoptotic receptor, although it retains one third of a consensus death domain motif in its cytoplasmic domain. It has been demonstrated that TRAILR4 expression is directly regulated by p53 and attenuates cell response to DNA-damaging agents.

References

1. Degli-Esposti MA. et al., 1997, Immunity. 7: 813-20.
2. Pan G. et al., 1998, FEBS Lett. 424: 41-5.
3. Shivapurkar N. et al., 2004, Int J Cancer. 109: 786-92.
4. Liu X. et al., 2005, Cancer Res. 65: 9169-75.
5. Baetu TM. et al., J. 2002, Cytokine Growth Factor Rev.13:199-207.